Introduction
============

Hypertension is a major risk factor for cardiovascular disease that contributes to the premature death of millions of people each year ([@b6-vhrm-4-1237]). The relationship between blood pressure and morbidity and mortality is linear ([@b22-vhrm-4-1237]; [@b6-vhrm-4-1237]); thus, the greater the reduction in blood pressure the greater the reduction in risk ([@b15-vhrm-4-1237]). Well defined targets for blood pressure have been established in treatment guidelines ([@b6-vhrm-4-1237]; [@b39-vhrm-4-1237]; [@b23-vhrm-4-1237]), and state that blood pressure targets should be \<140/90 mmHg, or \<130/80 mmHg for patients with diabetes or renal disease.

While the percentage of patients meeting these targets has increased in recent years ([@b6-vhrm-4-1237]), identification and treatment of hypertension continues to be a challenge. The vast majority of patients will require two or more antihypertensive agents from different classes ([@b15-vhrm-4-1237]; [@b8-vhrm-4-1237]; [@b9-vhrm-4-1237]; [@b6-vhrm-4-1237]), and in attempting to achieve the lower blood pressure target, or where a patient has more severe hypertension, three or more antihypertensive agents may be required ([@b6-vhrm-4-1237]). Guidelines recommend initiation of combination therapy when diastolic blood pressure (DBP) values are ≥10 mmHg above the DBP target or if SBP is ≥20 mmHg above the systolic blood pressure (SBP) target ([@b6-vhrm-4-1237]; [@b39-vhrm-4-1237]) and thus effective and well-tolerated combination therapies are required to manage patients who fail to respond to antihypertensive monotherapy.

For several years, thiazide diuretics such as hydrochlorothiazide (HCTZ) have been first-line treatment for hypertension ([@b30-vhrm-4-1237]; [@b6-vhrm-4-1237]; [@b29-vhrm-4-1237]), and several fixed-dose combinations with other classes of antihypertensive agents such as beta-blockers, angiotensinconverting enzyme (ACE) inhibitors, and angiotensin II receptor blockers (ARBs) are now available. While the mechanism of action for the antihypertensive effect of thiazides is not fully elucidated, it is known that they cause indirect activation of the renin-angiotensin system (RAS), providing a rationale for combining HCTZ with ACE inhibitors and ARBs. Thiazides lower blood pressure in patients with volume-sensitive hypertension, by induction of volume contraction. Volume contraction is a stimulus for renin release and elevation of background RAS activity. A high level of RAS activity is necessary for optimal blockade by an ACE inhibitor or an ARB. Combining an ARB with HCTZ has been shown in clinical studies to increase the antihypertensive efficacy of both agents compared with either agent alone ([@b3-vhrm-4-1237]; [@b17-vhrm-4-1237]; [@b9-vhrm-4-1237]). In contrast, while the antihypertensive effect of both drugs together is additive, a meta-analysis of combination therapy demonstrates that the prevalence of adverse events was less than would be expected with additive effects ([@b21-vhrm-4-1237]).

Olmesartan is the most recently introduced ARB, which has been shown to produce greater reductions in blood pressure than a range of antihypertensive agents including other ARBs ([@b1-vhrm-4-1237]; [@b31-vhrm-4-1237]; [@b35-vhrm-4-1237]; [@b4-vhrm-4-1237]). Olmesartan is also available as a fixed-dose combination with HCTZ. In this review, we examine the efficacy and safety of olmesartan plus HCTZ in a range of clinical cohorts, grouped according to study design, duration of treatment, and patient selection.

Clinical efficacy
=================

Evidence for the efficacy of olmesartan plus HCTZ, and the benefit of combination treatment over monotherapy with either agent, comes from 5 clinical trials. The design and features of these trials is shown in [Table 1](#t1-vhrm-4-1237){ref-type="table"}. Four of the studies were randomized, double-blind, multicenter studies that examined the efficacy of olmesartan alone or in combination with HCTZ using factorial dose-ranging design (2 studies); parallel group, HCTZ add-on design (1 study); or dose-titration, olmesartan add-on design (1 study). The fifth study was an open-label, dose-titration treat-to-target study in which patients received olmesartan in combination with HCTZ and/or amlodipine.

In all studies trough seated and standing blood pressure measurements were recorded with a standard mercury sphygmomanometer. Where ambulatory blood pressure monitoring (ABPM) was used, ABPM was recorded with a Spacelabs blood pressure monitor (Spacelabs GmbH, model 90207, Kaarst, Germany).

The primary efficacy end-point in the factorial studies and in the severe hypertension study was the change in trough seated DBP (seDBP) from baseline to the end of treatment (week 8, week 12, or the last post-baseline observation). Both DBP and SBP were measured at weeks 4, 8, and 12 of each study. The primary efficacy end-point in the HCTZ add-on cohort was the change in 24-hour mean ABPM between baseline (week 4 of treatment with HCTZ) and the end of treatment (week 12).

Each study reported the proportion of responders, defined in the factorial studies and the severe hypertension study as a mean seDBP \<90 mmHg or a decrease of ≥10 mmHg in seDBP at the end of treatment. In the HCTZ add-on study, responders were defined as having a mean daytime DBP of ≤85 mmHg as measured by 24-hour ABPM.

In all cases, the last observation carried forward (LOCF) method was used to impute missing values and all statistical tests were two sided with a p ≤ 0.05 defined as statistically significant. In the factorial studies, which included 12 treatment groups, the significance level in the ANCOVA was defined as 0.05 ÷ 12 (ie, p ≤ 0.004). ANCOVA was used to compare the change from baseline blood pressure (seated DBP or 24-hour ABPM) in the different dosage groups in the various studies. In the severe hypertension study the combination of olmesartan/HCTZ was declared to be non-inferior to the combination of atenolol/HCTZ if the upper limit of a 2-sided 95% confidence interval (CI) for the difference in least-squares means was ≤3.5 mmHg.

Placebo-controlled factorial design studies
-------------------------------------------

The two factorial studies ([@b7-vhrm-4-1237]; Daiichi-Sankyo, data on file) were of a sufficiently similar design to allow pooling and integration of data. This was conducted in an Integrated Summary of Efficacy, as shown in [Table 1](#t1-vhrm-4-1237){ref-type="table"} (Daiichi-Sankyo, Integrated Summary of Efficacy, data on file). The studies were factorial dose-ranging studies designed to identify the optimum combination doses and to show that the combination for olmesartan and HCTZ is superior to each component alone. Response surface techniques using quadratic modeling were also used to model the optimal response within the range of experimental doses. Treatment was with olmesartan 0, 10, 20, and 40 mg and HCTZ 0, 12.5, and 25 mg in all possible combinations.

The total ITT population in these pooled studies comprised 1986 patients. Of these, 979 received combination therapy; 498 olmesartan/placebo; 344 HCTZ/placebo; and 165 placebo only. The numbers of patients and their baseline characteristics were generally similar among the 12 treatment groups and an overview is shown in [Table 2](#t2-vhrm-4-1237){ref-type="table"}. Most patients in all treatment groups were Caucasian the mean age ranged from 53.4 to 55.3 years, and most patients in all treatment groups were \<65 years of age.

A dose-dependent decrease from baseline in seDBP was seen with respect to both the olmesartan and HCTZ components ([Figure 1a](#f1-vhrm-4-1237){ref-type="fig"}). Combination treatment with the higher doses of each monotherapy component produced substantial decreases from baseline in seDBP, with reductions of 19.6 and 20.1 mmHg seen when olmesartan 20 mg and 40 mg, respectively were added to HCTZ 25 mg. All combinations of olmesartan/HCTZ were significantly more effective compared with the respective dose of HCTZ monotherapy ([Figure 1c](#f1-vhrm-4-1237){ref-type="fig"}) and all combinations of olmesartan/HCTZ 25 mg were significantly more effective than the respective dose of olmesartan monotherapy ([Figure 1c](#f1-vhrm-4-1237){ref-type="fig"}).

Decreases from baseline in seSBP at the primary endpoint paralleled those of seDBP, although reductions in mean seSBP were generally greater than the reductions in mean seDBP. The reductions were mainly dose-related for both olmesartan and HCTZ components ([Figure 1b](#f1-vhrm-4-1237){ref-type="fig"}). Combination treatment with the higher doses of each component produced substantial decreases from baseline in seSBP, with reductions of at least 26 mmHg seen when olmesartan 20 mg and 40 mg, respectively were added to HCTZ 25 mg.

For both seDBP and seSBP, the effects of olmesartan and HCTZ were additive, which was confirmed using response surface modeling. When the analysis was restricted to the range of doses tested, the optimal dose of olmesartan/HCTZ for SBP reductions was estimated to be 27.1 mg/24.2 mg (estimated to produce a mean decrease of 27.6 mmHg) and for DBP reduction was estimated to be 27.6 mg/24.1 mg (estimated to produce a mean decrease of 20.6 mmHg). In practical terms, the optimal dose corresponds to the olmesartan/HCTZ 20 mg/25 mg and 40 mg/25 mg combinations.

The proportion of patients with a treatment response was higher for combination therapy than with either component alone ([Table 3](#t3-vhrm-4-1237){ref-type="table"}). Response rates were consistently higher in patients receiving olmesartan/HCTZ combination therapy than in those receiving the same respective doses of olmesartan or HCTZ with placebo. Among patients treated with olmesartan/HCTZ 20 mg/25 mg or 40 mg/25 mg, more than 90% of patients were responders.

HCTZ add-on study
-----------------

Conventional blood pressure measurements may be affected by so-called "white-coat hypertension" ([@b28-vhrm-4-1237]), in which a patient's anxiety may cause increases in blood pressure during monitoring in the clinic. Ambulatory blood pressure monitoring (ABPM) may offer a more accurate picture of a patient's blood pressure over the course of the day, and may therefore further demonstrate the efficacy of an antihypertensive agent over a 24-hour period ([@b27-vhrm-4-1237]).

The effect of adding either 12.5 mg or 25 mg HCTZ to olmesartan 20 mg on ABPM in patients whose DBP (measured by standard mercury sphygmomanometer) continued to be ≥90 mmHg after 4 weeks of treatment with olmesartan 20 mg monotherapy was assessed in a partially randomized, placebo-controlled trial ([@b34-vhrm-4-1237]). The ITT population comprised 535 individuals, with a total of 174, 184 and 177 patients randomized to the olmesartan 20 mg/placebo, olmesartan 20 mg/HCTZ 12.5 mg and olmesartan 20 mg/HCTZ 25 mg groups, respectively.

Additional analysis of data from this study in the Integrated Summary of Efficacy described above has determined that at baseline the mean daytime DBP as measured by 24-hour ABPM ranged from 88.3 mmHg to 89.5 mmHg across the three treatment groups (Daiichi-Sankyo, Integrated Summary of Efficacy, data on file). After 12 weeks of treatment the mean change in daytime DBP (the primary outcome) was significantly greater in patients treated with either olmesartan/HCTZ 20 mg/12.5 mg (−2.67 mmHg; p = 0.01) or 20 mg/25 mg (−4.56 mmHg; p \< 0.0001) than with olmesartan 20 mg/placebo ([Table 4](#t4-vhrm-4-1237){ref-type="table"}). Consistent with the primary outcome, the combination of olmesartan 20 mg/HCTZ 25 mg produced statistically significant reductions in night-time DBP (p = 0.0011), and in both daytime and night-time SBP and 24-hour DBP and SBP (all p \< 0.0001) compared with olmesartan/placebo 20 mg.

Significant differences between the combination therapy groups and monotherapy was also demonstrated using conventional blood pressure measurement. After 12 weeks of treatment, reductions in mean trough seated DBP (p = 0.001) and SBP (p = 0.0002) were significantly greater with olmesartan 20 mg/HCTZ 25 mg than with olmesartan/placebo.

The proportion of responders was greatest in patients treated with olmesartan 20 mg/HCTZ 25 mg (70.7%) or olmesartan 20 mg/HCTZ 12.5 mg (58.6%) than with olmesartan/placebo (49.4%).

Once again, olmesartan and HCTZ were demonstrated to have additive effects. The use of ABPM confirmed that olmesartan/HCTZ provides effective control throughout the 24-hour dosage interval, including during the early hours of the morning when the risk of cardiovascular events is highest.

Severe hypertension cohort
--------------------------

Moderate to severe hypertension (SBP ≥160 and/or DBP ≥100) ([@b23-vhrm-4-1237]; [@b39-vhrm-4-1237]) not only puts patients at greater risk for cardiovascular events, but is also more difficult to treat, with almost all patients requiring 2 or more antihypertensive agents. In 328 patients with moderate to severe essential hypertension, the efficacy of a combination of olmesartan and HCTZ was compared with atenolol in a non-inferiority, dose titration study ([@b1-vhrm-4-1237]). A 4-week single-blind placebo run-in phase was followed by single-blind treatment with HCTZ 25 mg for 4 weeks. Patients whose DBP was 100--120 mmHg after 4 weeks of HCTZ monotherapy were randomized to 12 weeks' treatment with olmesartan 10 mg/HCTZ 25 mg (n = 164) or atenolol 50 mg/HCTZ 25 mg (n = 164). If mean seated DBP was ≥90 mm Hg and/or the decrease in mean seated DBP from baseline was \<10 mm Hg after 4 weeks' combination therapy, the dose of olmesartan or atenolol was doubled (ie, patients received olmesartan 20/HCTZ 25 mg or atenolol 100 mg/HCTZ 25 mg for the final 8 weeks of the treatment phase).

At baseline mean trough seated SBP/DBP was 160.9/104.9 mm Hg and 161.7/105.3 mmHg in patients randomized to olmesartan/HCTZ and atenolol/HCTZ, respectively (Daiichi-Sankyo, Integrated Summary of Efficacy, data on file).

After 12 weeks of treatment, the proportion of responders was 88.7% and 86.3%, respectively among those treated with olmesartan/HCTZ and atenolol/HCTZ. The least squares mean reduction in trough seated SBP/DBP was −21.1/−17.6 mmHg with olmesartan/HCTZ and −20.3/−17.5 mmHg with atenolol/HCTZ. The upper limit of the 95% CI for the difference in least squares means of DBP in the two treatment groups was 1.18 mmHg. This was below the 3.5 mmHg defined as the non-inferiority limit, and so the combination of olmesartan (titrated up to the optimal dose of 20 mg) and HCTZ was shown to be at least as effective as atenolol (titrated up to the maximal dose of 100 mg) plus HCTZ in terms of lowering DBP (Daiichi-Sankyo, Integrated Summary of Efficacy, data on file).

Treat-to-target study
---------------------

The majority of trials of antihypertensive agents concentrate on the mean reductions in blood pressure. However, many patients who respond to therapy (ie, have a reduction from baseline in DBP) may not achieve the target BP of \<140/90 mmHg (or \<130/85 for high-risk patients) ([@b6-vhrm-4-1237]; [@b23-vhrm-4-1237]). The efficacy of olmesartan as part of a forced titration algorithm that involved 6 sequential treatment steps, each of 4 weeks' duration, to achieve a target BP of ≤130/≤85 mmHg has been assessed ([@b26-vhrm-4-1237]; [@b25-vhrm-4-1237]). As part of this algorithm, patients not only received olmesartan in combination with HCTZ, but also as part of a triple combination with HCTZ and amlodipine.

The algorithm was as follows: olmesartan 20 mg, olmesartan 40 mg, olmesartan/HCTZ 40 mg/12.5 mg, olmesartan/HCTZ 40 mg/25 mg, olmesartan/HCTZ/amlodipine 40 mg/12.5 mg/5 mg, and olmesartan/HCTZ/amlodipine 40 mg/12.5 mg/10 mg. Treatment at each step was continued for 4 weeks and if the patient had not reached the goal BP, they advanced to the next step.

In a further analysis of the data derived from this study, mean changes from treatment baseline were calculated for DBP and SBP using observations before each step in the algorithm, and are demonstrated in [Figure 2a](#f2-vhrm-4-1237){ref-type="fig"} and b (Daiichi-Sankyo, Integrated Summary of Efficacy, data on file). Further analysis examining the proportion of patients achieving the target blood pressure of ≤140/≤90 mmHg showed that at the end of the second step, when the maximal dose of olmesartan was being used, 57.5% of the 198 patients had reached target. At the end of the 4th treatment step, when the maximum doses of olmesartan and HCTZ were being used, the proportion of patients who had reached the ≤140/≤90 mmHg target was 82.1%. When the analysis used the more stringent target of ≤130/≤85 mmHg, the proportion of patients who had reached target at the end of the second and fourth steps was 33.0 and 65.4%, respectively ([Figure 2c](#f2-vhrm-4-1237){ref-type="fig"}) (Daiichi-Sankyo, Integrated Summary of Efficacy, data on file). The addition of amlodipine produced further reductions in BP so that by the end of the sixth treatment step (study end), when the maximum dose of all three agents was being used, the proportion of patients achieving the ≤140/≤90 and ≤130/≤85 mmHg goals was 92.7 and 83.8%, respectively.

Given the estimate that only around one-third of patients have their blood pressure controlled to below 140/90 mmHg ([@b6-vhrm-4-1237]), the use of a stepped treatment approach such as this where over 90% of all patients, and more than 95% of patients with stage 1 hypertension (Daiichi-Sankyo, Integrated Summary of Efficacy, data on file) may reach this level shows great potential.

Long-term studies
-----------------

Since patients with hypertension may require ongoing therapy, the ability of olmesartan in combination with HCTZ to provide effective blood pressure reduction over the long term has also been evaluated. A total of 1190 of the 1986 randomized patients who were responders in one of the placebo-controlled factorial studies (Daiichi-Sankyo, Integrated Summary of Efficacy, data on file) entered a 40-week long-term extension study, and of these, 74 patients received placebo, 288 patients received olmesartan alone, 178 patients received HCTZ alone, and 650 patients received combination therapy.

Notable decreases from baseline to last visit were seen for all treatment responders, and, as seen in the 12-week double-blind phase of the study, these greater decreases were seen in the combination therapy groups than in the placebo or monotherapy groups ([Figure 3](#f3-vhrm-4-1237){ref-type="fig"}). The between-group differences were greater for SBP than DBP, and this could be expected due to the fact that this cohort of patients was permitted to continue in the extension phase only if they were already treatment responders.

Patients who received olmesartan/HCTZ 20 mg/25 mg or 40 mg/25 mg achieved mean trough seated SBP/DBP of \<140/90 mmHg at the end of treatment.

The second placebo-controlled factorial study ([@b7-vhrm-4-1237]) allowed patients to continue receiving open-label treatment for 4 months with olmesartan/HCTZ 20 mg/12.5 mg, titrating HCTZ to 25 mg in 53/340 patients whose blood pressure was poorly controlled on the lower dose (Daiichi-Sankyo, Integrated Summary of Efficacy, data on file). Blood pressure was reduced in patients receiving both treatment regimens, to a mean of 128.1/83.2 in patients receiving the lower dose of HCTZ and to a mean of 138.6/91.9 in patients requiring HCTZ 25 mg.

The long-term extension results from these two studies demonstrate that the blood pressure lowering effects of combination therapy are maintained over time, and reiterate the additive effects of olmesartan and HCTZ.

Safety
======

An Integrated Summary of Safety was conducted in order to analyze the adverse events that occurred during the studies listed above (Daiichi-Sankyo, Integrated Summary of Safety, data on file). In the placebo-controlled factorial studies, dizziness was the most commonly reported adverse event in patients receiving olmesartan/HCTZ combination therapy, although no adverse event was significantly more frequent than another. Interestingly, dizziness became less common over time, as patients who continued into the long-term extension phase reported fewer incidences.

In the HCTZ add-on study, the incidence of adverse events was low, with 6.1%--6.6% of patients reporting at least one adverse event across the treatment groups. A total of 6 patients in this study withdrew from the study due to adverse events, all of whom were receiving olmesartan monotherapy. These findings suggest that the addition of HCTZ to olmesartan does not increase the incidence of adverse events.

In the severe hypertensive cohort, patients receiving olmesartan/HCTZ combination therapy experienced fewer adverse events than patients receiving the atenolol/HCTZ combination (34.8 versus 37.2%). Events such as headache, dizziness and vertigo were more frequent in the olmesartan/HCTZ group. Although 2 patients in the olmesartan/HCTZ group compared with 1 patient in the atenolol/HCTZ group experienced a treatment emergent severe adverse event, none of these events were considered to be related to study medication.

The pattern was again similar in the treat-to-target cohort, in which the overall incidence of treatment emergent adverse events was about 40%. Most of these events were considered unrelated to the study medication, and were mild or moderate.

Across all the studies described here, 44% of patients on combination therapy, 49% of placebo patients, 41% of HCTZ patients and 47% of olmesartan patients reported treatment-emergent adverse events (Daiichi-Sankyo, Integrated Summary of Safety, data on file). Most adverse events were mild or moderate in nature, with only 6% of events reported as severe. Overall, 20% of adverse events were considered to be treatment related. The frequencies of discontinuations due to adverse events were similar across olmesartan monotherapy (2.7%), HCTZ monotherapy (3.2%), combination therapy (2.3%) and placebo groups (3.0%). Four patient deaths were recorded in one of the placebo-controlled factorial studies, but only one of these was considered possibly related to study medication. Overall, the proportion of adverse events considered to be treatment related, and the low proportion of severe adverse events reported indicate that olmesartan and HCTZ are well-tolerated therapies, alone and in combination.

Discussion
==========

The clinical studies included in this review demonstrate that olmesartan combined with HCTZ provides a high degree of clinical efficacy combined with good tolerability. Dose-ranging data have demonstrated that the combination of olmesartan and HCTZ produces dose-dependent increases in BP-reducing efficacy (Daiichi-Sankyo, data on file). This review provides further evidence of this by combining data from two dose-ranging studies that used a similar factorial design and methodology. The add-on study was included since it demonstrates the effect of adding HCTZ to patients already receiving olmesartan and the treat-to-target study is important since it illustrates that a stepped approach to antihypertensive treatment based upon olmesartan and HCTZ can increase the numbers of patients who achieve BP targets. The study in patients with moderate-to-severe hypertension was included to illustrate the efficacy of the combination in these harder-to-treat patients.

With the large number of patients worldwide whose hypertension remains poorly controlled, there is a clear clinical need for effective and well-tolerated therapies that combine different antihypertensive agents. In fact more than two-thirds of patients with hypertension will require combination therapy with two or more antihypertensive agents from different drug classes to achieve target blood pressure ([@b8-vhrm-4-1237]; [@b6-vhrm-4-1237]). Thiazide diuretics such as HCTZ continue to form the foundation of anti-hypertensive therapy and their mechanism of action is complementary to that of ARBs, enhancing the efficacy of both agents. This effect is demonstrated in the pooled data from the two factorial studies that demonstrate that the blood pressure lowering effects of olmesartan and HCTZ are additive, in that combination therapy with olmesartan and HCTZ is significantly better than monotherapy with either drug, except when low-dose combinations are used. In addition, the percentage of patients responding to therapy (\>10 mmHg decrease from baseline) is higher in patients receiving combination therapy than in those receiving mono-therapy, and decreases from baseline in both DBP and SBP are dose related.

The findings of the studies described in this review are supported by other studies in which the efficacy of olmesartan in combination with HCTZ has been assessed ([@b2-vhrm-4-1237]; [@b16-vhrm-4-1237]). In the OLMEBEST study, patients with mild-to-moderate hypertension who had a DBP \<90 mmHg after 8 weeks of open label treatment with olmesartan 20 mg randomly received olmesartan 40 mg or olmesartan 20 mg/HCTZ 12.5 mg for a further 4 weeks. Each randomized treatment led to a further reduction in BP beyond that produced by the open label treatment. At the end of the randomized treatment phase, patients who had received olmesartan 20 mg/HCTZ 12.5 mg showed larger a change in SBP and DBP (−10.8 and −7.9 mmHg, respectively) than the olmesartan 40 mg group (−5.3 and −5.1 mmHg), although these differences were not significant ([@b2-vhrm-4-1237]). In addition, a forced titration regimen beginning with olmesartan monotherapy (20 followed by 40 mg) followed by the addition of HCTZ (12.5 followed by 25 mg) was compared with forced titration based upon benazepril monotherapy (10 followed by 20 mg) to which amlodipine (5 followed by 10 mg) was added ([@b16-vhrm-4-1237]). At study end, the olmesartan/HCTZ group showed a significantly larger change in SBP (−32.5 mmHg; primary endpoint) than the the benazepril/amlodipine group (−26.5 mmHg, p = 0.024). Also, a significantly greater proportion of patients achieved the BP goals of \<140/90, 130/85, and 130/80 mmHg (66.3, 44.9, and 32.6%, respectively) with olmesartan/HCTZ compared with the benazepril/amlodipine group (44.7, 21.2, and 14.1%) ([@b16-vhrm-4-1237]).

When given as monotherapy, olmesartan produces greater reductions in blood pressure than a range of other agents in this class ([@b4-vhrm-4-1237]). While this current review does not compare the combination of olmesartan and HCTZ with other ARB/HCTZ combinations, previous studies have been conducted examining the efficacy of other ARBs in combination with HCTZ. Candesartan, telmisartan, losartan and valsartan have all been used in combination with HCTZ, and have demonstrated blood pressure lowering in the range of 4.5--9 mmHg for DBP and in the range of 6.8--12.6 mmHg for SBP, compared with monotherapy regimens ([@b5-vhrm-4-1237]; [@b20-vhrm-4-1237]; [@b36-vhrm-4-1237]; [@b19-vhrm-4-1237]; [@b18-vhrm-4-1237]; [@b37-vhrm-4-1237]). A published systematic review examining factorial design trials of ARBs combined with HCTZ demonstrated that after 8 weeks of therapy, olmesartan plus HCTZ achieved the greatest reductions in DBP and SBP when compared with irbesartan/HCTZ, telmisartan/HCTZ, and valsartan/HCTZ ([@b32-vhrm-4-1237]). While such a review of the literature is limited due to inherent differences in the design of the factorial studies as well as the lack of statistical analysis of findings, it does demonstrate the efficacy of ARB/HCTZ combinations in general, and supports further research in the form of head-to-head trials. A recently published meta-analysis of the antihypertensive efficacy of ARBs in studies using 24-hour ABPM found differences in both the magnitude and duration of antihypertensive activity between ARBs ([@b14-vhrm-4-1237]). Although the analysis was not designed to determine which ARB had the greatest efficacy, the data presented showed that BP reductions were generally greater with olmesartan, including in the critical last four hours of the interdose period. This review also demonstrated that adding HCTZ to ARBs provided further additional reduction in BP.

The results presented here demonstrate that olmesartan is highly effective when added to ongoing HCTZ monotherapy or, conversely, when HCTZ is added to ongoing olmesartan monotherapy. Moderate to severe hypertension also responds well to olmesartan therapy, and efficacy continues to be maintained over the long term.

A further analysis of the treat-to-target study has shown that in patients with stage 1 hypertension (baseline SBP 140--159 mmHg or DBP 90--99 mmHg) at the end of the 4th treatment step, when the high doses of olmesartan and HCTZ were being used, mean trough seated DBP was ≤90 mmHg in 97.5% of patients, and ≤85 mmHg in 94.9% of patients, and 93.7% of patients had achieved a combined BP goal of ≤140/90 mmHg ([@b25-vhrm-4-1237]). In patients with the more severe stage 2 hypertension (baseline SBP ≥160 mmHg or DBP ≥100 mmHg), the respective proportions of patients with DBP ≤90 and ≤85 mmHg were 95.0 and 81.0% and 75.0% of patients had achieved the combined BP goal of ≤140/90 mmHg at the end of the 4th treatment step. The addition of amlodipine to this stepped treatment protocol produced even greater percentages of goal rate achievement in each group of patients ([@b25-vhrm-4-1237]).

These goal rate results obtained with olmesartan plus HCTZ appear to be reproducible for other ARB combinations. The combination of losartan and HCTZ has also been shown to be significantly better than monotherapy in achieving goal rates, although the percentage of patients reaching goal was smaller overall ([@b33-vhrm-4-1237]).

The use of ABPM may offer additional benefits in measuring BP over a 24-hour period, and may be especially important in assessing patients at increased risk of cardiovascular events ([@b6-vhrm-4-1237]). As well as olmesartan, other ARB/HCTZ combinations have been assessed using ABPM ([@b19-vhrm-4-1237]; [@b13-vhrm-4-1237]; [@b24-vhrm-4-1237]; [@b38-vhrm-4-1237]) and consistently show that combination therapy results in greater decreases from baseline and higher response rates throughout the entire 24-hour period than placebo or monotherapy.

While the efficacy of olmesartan and HCTZ has been proven to be additive, a previous meta-analysis of combination therapy has demonstrated that the prevalence of adverse events was significantly lower than would be expected with an additive effect ([@b21-vhrm-4-1237]). The studies analyzed in this review confirm that the combination of olmesartan/HCTZ is well tolerated, and that the incidence of adverse events is similar in combination and monotherapy groups.

Conclusion
==========

Olmesartan plus HCTZ produces additive reductions in blood pressure and, when given at the optimal dose 20/25 mg or 40/25 mg, produces double-digit reductions in DBP and SBP. Thus olmesartan/HCTZ is a well-tolerated option for patients who fail to respond to monotherapy and as initial therapy in those who require large reductions in DBP or SBP to achieve goal blood pressure.
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###### 

Summary of studies examining the efficacy and safety of olmesartan medoxomil plus HCTZ

  Study reference                                                                                                     Design                                                                              Entry criteria                                                                                                                         Primary efficacy endpoint                                                                                                                                                  Treatment arms/drug dosages
  ------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------
  Pooled factorial design studies ([@b7-vhrm-4-1237]; Daiichi-Sankyo, Integrated Summary of Efficacy, data on file)   Randomized, db, pc, pg, mc, factorial design                                        Mean seDBP 100--115 mmHg at weeks 3 and 4 of placebo run-in                                                                            Change from baseline in mean trough seDBP at week 8 or 12                                                                                                                  Placebo OLM (10, 20 or 40 mg/day) HCTZ (12.5 or 25 mg/day) OLM plus HCTZ (all combinations)
  HCTZ add-on cohort ([@b34-vhrm-4-1237])                                                                             Partially randomized, db, pc, pg, mc                                                Mean seDBP 100--115 mmHg and mean 24-hour DBP (by ABPM) ≥84 mmHg; ≥30% daytime DBP \>90 mmHg; seDBP ≥90 mmHg after olmesartan run-in   Change from baseline to end of study (week 12) in mean daytime DBP (by ABPM)                                                                                               OLM (20 mg/day) OLM plus HCTZ (20 mg/day plus 12.5 or 25 mg/day
  Severe hypertensive cohort ([@b1-vhrm-4-1237])                                                                      Randomized, db, pg, mc, double-dummy, dose-titration, comparison study              Moderate--severe essential 1 (seDBP 100--120 mmHg) at end of HCTZ run-in.                                                              Change from baseline in mean trough seDBP at week 12                                                                                                                       OLM plus HCTZ (10 or 20 mg/day plus 25 mg/day) Atenolol plus HCTZ (50 or100 mg plus 25 mg/day)
  Treat-to-target cohort ([@b26-vhrm-4-1237], [@b25-vhrm-4-1237])                                                     Open-label, non-comparative, mc, treat-to-target, with 6-step treatment algorithm   Mean seDBP 90--109 mmHg                                                                                                                Change from study baseline/treatment baseline to the end of each 4-week period using the LOCF in seDBP and seSBP and number of responders (SBP ≤130 mmHg, DBP ≤85 mmHg).   OLM (20 or 40 mg/day) OLM plus HCTZ (40 mg/day plus 12.5 or 25 mg/day) OLM plus HCTZ plus amlodipine (40 mg/day plus 25 mg/day plus 5 or 10 mg/day)

**Abbreviations:** ABPM, ambulatory blood pressure monitoring; db, double-blind; HCTZ, hydrochlorothiazide; LOCF, last observation carried forward; mc, multicenter; OLM, olmesartan medoxomil; pc, placebo-controlled; pg, parallel-group; seDBP, seated diastolic blood pressure; seSBP, seated systolic blood pressure.

###### 

Comparison of demographic and baseline characteristics across studies assessing olmesartan and HCTZ

  Study                                                                                                               No. patients   Mean age (years)   Sex (% male)   Ethnicity (% caucasian)   Hypertension history (years)   Mean baseline seated BP   
  ------------------------------------------------------------------------------------------------------------------- -------------- ------------------ -------------- ------------------------- ------------------------------ ------------------------- ------------------------------------------------------------
  Pooled factorial design studies ([@b7-vhrm-4-1237]; Daiichi-Sankyo, Integrated Summary of Efficacy, data on file)   1986           53.4--55.3         52.1%          93.5%                     6.8--7.6                       157.2--160.7^a^           103.6--104.3^a^
  HCTZ add-on cohort ([@b34-vhrm-4-1237])                                                                             535            52--54             55.0%          100%                      6.9--7.2                       147.4--150.4^a^           95.3--95.8^a^
  Severe hypertensive cohort ([@b1-vhrm-4-1237])                                                                      328            55.4--55.6         47.9%          100%                      6.2--6.8                       160.9--161.7^a^           104.9--105.3^[\*](#tfn3-vhrm-4-1237){ref-type="table-fn"}^
  Treat-to-target cohort ([@b26-vhrm-4-1237]; [@b25-vhrm-4-1237])                                                     198            52.8               65.2%          73.7%                     8.3                            161.2                     96.6

**Abbreviations:** DBP, diastolic blood pressure; HCTZ, hydrochlorothiazide; SBP, systolic blood pressure.

mean for each treatment group (lowest and highest mean values).

###### 

Percentage of patients with a treatment response in the combined factorial studies

  HCTZ (mg)   OLM (mg)                   
  ----------- ---------- ------- ------- -------
  **0**       60.4%      79.5%   78.4%   81.1%
  **12.5**    69.8%      89.7%   88.1%   92.7%
  **25**      76.9%      95.6%   94.1%   92.7%

**Abbreviations:** HCTZ, hydrochloroziazide; OLM, olmesartan medoxomil.

###### 

Comparison of 24-hour ABPM values: change from baseline to week 12 -- HCTZ add-on study

                                 Olmesartan 20 mg                                
  ------------------------------ ----------------------- ----------------------- -------------------------
  Daytime DBP LSM (95% CI)       −2.22 (−3.71, −0.73)    −4.89 (−6.34, −3.45)    −6.78 (−8.26, −5.30)
  Night-time DBP LSM (95% CI)    −2.79 (−4.23, −1.35)    −4.28 (−5.69, −2.87)    −6.08 (−7.52, −4.65)
  24-hour DBP LS mean (95% CI)   −2.62 (−3.94, −1.29)    −4.75 (−6.04, −3.46)    −6.58 (−7.90,−5.27)
  Daytime SBP LSM (95% CI)       −2.96 (−5.21, 0.72)     −8.00 (−10.17, −5.83)   −11.70 (−13.94, (−9.47)
  Night-time SBP LSM (95% CI)    −3.49 (−5.66, −1.32)    −7.22 (−9.33, −5.11)    −10.89 (−13.05, −8.74)
  24-hour SBP LSM (95% CI)       −3.32, (−5.40, −1.24)   −7.74 (−9.76, −5.73)    −11.37, (−13.44, −9.30)

**Abbreviations:** ABPM, ambulatory blood pressure monitoring; CI, confidence intervals; DBP, diastolic blood pressure; HCTZ, hydrochlorothiazide; LSM, least squares mean; SBP, systolic blood pressure.
